Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis

Objective: Despite advancements in treatment, multiple myeloma (MM) remains a challenging hematologic malignancy. It is crucial to stratify risk and perform prognostic assessment with various markers, including the expression of cluster of differentiation 56 (CD56) and cluster of differentiation 117...

Full description

Saved in:
Bibliographic Details
Main Authors: Hakan Keski, Selim Merdan, Itır Ebru Zemheri
Format: Article
Language:English
Published: Galenos Publishing House 2024-12-01
Series:Turkish Journal of Hematology
Subjects:
Online Access:https://tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-14306
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846141504156860416
author Hakan Keski
Selim Merdan
Itır Ebru Zemheri
author_facet Hakan Keski
Selim Merdan
Itır Ebru Zemheri
author_sort Hakan Keski
collection DOAJ
description Objective: Despite advancements in treatment, multiple myeloma (MM) remains a challenging hematologic malignancy. It is crucial to stratify risk and perform prognostic assessment with various markers, including the expression of cluster of differentiation 56 (CD56) and cluster of differentiation 117 (CD117). However, the relationship of these markers with MM-related survival remains unclear. In this context, the objective of this study was to investigate the prognostic implications of CD56 and CD117 expression and associated clinical features in MM patients. Materials and Methods: The population of this retrospective single-center study consisted of adult MM patients whose CD56 and CD117 expression levels were analyzed. Patients were divided into four groups according to their immunophenotypes: CD56+CD117-, CD56-CD117+, CD56+CD117+, and CD56-CD117-. These groups were compared in terms of demographic and clinical characteristics, response to treatment, and survival outcomes. Results: Of the 168 MM patients included in the study, CD56 positivity, CD117 positivity, CD56 and CD117 double positivity, and CD56 and CD117 double negativity were observed in 57.1%, 38.1%, 21.4%, and 26.2%, respectively. Patients with double positivity had significantly higher cytogenetic risk and significantly lower overall response rate (ORR) compared to other patients (p<0.001 for both). ORR and overall survival (OS) were significantly lower in CD56-positive patients than in CD56-negative patients (p=0.017 and p=0.004, respectively). Mortality rates were significantly higher in CD56-positive and CD117- positive patients than in double-negative patients (p<0.001 and p=0.002, respectively). Double-negative patients had significantly lower ORR and OS and higher mortality than others (p=0.001, p=0.002, and p<0.001, respectively). High cytogenetic risk was found to be an independent predictor of shorter OS (p>0.001). Conclusion: This study’s findings revealed that MM patients with CD56 and CD117 double positivity had poorer prognosis, lower ORR, shorter OS, and higher mortality.
format Article
id doaj-art-2d9f867f266640a2ae09e2476db92e65
institution Kabale University
issn 1308-5263
language English
publishDate 2024-12-01
publisher Galenos Publishing House
record_format Article
series Turkish Journal of Hematology
spelling doaj-art-2d9f867f266640a2ae09e2476db92e652024-12-04T06:39:46ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632024-12-0141423624510.4274/tjh.galenos.2024.2024.0149Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective AnalysisHakan Keski0https://orcid.org/0000-0002-5644-823XSelim Merdan1https://orcid.org/0009-0008-7036-1115Itır Ebru Zemheri2https://orcid.org/0000-0003-0247-0332University of Health Sciences Türkiye, Ümraniye Training and Research Hospital, Clinic of Hematology, İstanbul, TürkiyeUniversity of Health Sciences Türkiye, Ümraniye Training and Research Hospital, Clinic of Microbiology, İstanbul, TürkiyeUniversity of Health Sciences Türkiye, Ümraniye Training and Research Hospital, Clinic of Pathology, İstanbul, TürkiyeObjective: Despite advancements in treatment, multiple myeloma (MM) remains a challenging hematologic malignancy. It is crucial to stratify risk and perform prognostic assessment with various markers, including the expression of cluster of differentiation 56 (CD56) and cluster of differentiation 117 (CD117). However, the relationship of these markers with MM-related survival remains unclear. In this context, the objective of this study was to investigate the prognostic implications of CD56 and CD117 expression and associated clinical features in MM patients. Materials and Methods: The population of this retrospective single-center study consisted of adult MM patients whose CD56 and CD117 expression levels were analyzed. Patients were divided into four groups according to their immunophenotypes: CD56+CD117-, CD56-CD117+, CD56+CD117+, and CD56-CD117-. These groups were compared in terms of demographic and clinical characteristics, response to treatment, and survival outcomes. Results: Of the 168 MM patients included in the study, CD56 positivity, CD117 positivity, CD56 and CD117 double positivity, and CD56 and CD117 double negativity were observed in 57.1%, 38.1%, 21.4%, and 26.2%, respectively. Patients with double positivity had significantly higher cytogenetic risk and significantly lower overall response rate (ORR) compared to other patients (p<0.001 for both). ORR and overall survival (OS) were significantly lower in CD56-positive patients than in CD56-negative patients (p=0.017 and p=0.004, respectively). Mortality rates were significantly higher in CD56-positive and CD117- positive patients than in double-negative patients (p<0.001 and p=0.002, respectively). Double-negative patients had significantly lower ORR and OS and higher mortality than others (p=0.001, p=0.002, and p<0.001, respectively). High cytogenetic risk was found to be an independent predictor of shorter OS (p>0.001). Conclusion: This study’s findings revealed that MM patients with CD56 and CD117 double positivity had poorer prognosis, lower ORR, shorter OS, and higher mortality.https://tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-14306multiple myelomacytogenetic abnormalitiescd56cd117survival
spellingShingle Hakan Keski
Selim Merdan
Itır Ebru Zemheri
Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis
Turkish Journal of Hematology
multiple myeloma
cytogenetic abnormalities
cd56
cd117
survival
title Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis
title_full Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis
title_fullStr Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis
title_full_unstemmed Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis
title_short Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis
title_sort evaluation of cd56 and cd117 double positivity as a predictor of poor prognosis in multiple myeloma patients a retrospective analysis
topic multiple myeloma
cytogenetic abnormalities
cd56
cd117
survival
url https://tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-14306
work_keys_str_mv AT hakankeski evaluationofcd56andcd117doublepositivityasapredictorofpoorprognosisinmultiplemyelomapatientsaretrospectiveanalysis
AT selimmerdan evaluationofcd56andcd117doublepositivityasapredictorofpoorprognosisinmultiplemyelomapatientsaretrospectiveanalysis
AT itırebruzemheri evaluationofcd56andcd117doublepositivityasapredictorofpoorprognosisinmultiplemyelomapatientsaretrospectiveanalysis